Although curative treatment of cervical esophageal cancer is mainly based on surgical resection, refusal of surgery is particularly common when it involves laryngectomy. Also, some cases are unresectable. Guidelines recommend definitive chemoradiotherapy with cisplatin and fluorouracil as a non-surgical treatment. On the other hand, the triplet regimen DCF-R, which includes docetaxel, has also been reported for thoracic esophageal cancer. We retrospectively evaluated the efficacy and safety of DCF-R for cervical esophageal cancer. Four cases who received DCF-R for cervical esophageal cancer in our hospital, from 12/1/09 to 3/1/2020. Age 55-72 years, male:female 3:1, all patients had squamous cell carcinoma, T3-4bN1M0-1LYM, cStageIVA-IVB (UICC 8th). There were no cases with distant metastases other than supraclavicular lymph node metastasis. Chemoradiotherapy include Docetaxel 35 mg/m2 div days1, 15, 29, Cisplatin 40 mg/m2 div days1, 15, 29, 5-FU 400 mg/m2 div days1-5, days15-19, days29-33, radiation 60 Gy (2 Gy/ Fr x 30 Fr), additional chemotherapy Docetaxel 40 mg/m2 div day 57, 85, Cisplatin 60 mg/m2 div day 57, 85, 5-FU 600 mg/m2 div day 57-61, 85-89. The efficacy of treatment and adverse events in the subjects were examined retrospectively. The completion rate of chemoradiotherapy was 100%, survival time 7 months death/3 years death/6 years survival/7 years survival, 3 complete response, and all patients had Grade 3 or greater neutropenia/Grade 2 esophagitis, respectively. After treatment, all patients were able to take meals orally. DCF-R is a feasible and potentially effective treatment option for cervical esophageal cancer. We are planning a phase II trial of DCF-R for cervical esophageal cancer.